The third generation oral contraceptive controversy
- 25 September 1999
- Vol. 319 (7213) , 795-796
- https://doi.org/10.1136/bmj.319.7213.795
Abstract
Papers p 820 New evidence on myocardial infarction and the recent statement from the Medicines Commission giving a greater role to clinical judgment in choosing a contraceptive pill1 call for a reassessment of the role of third generation oral contraceptives containing desogestrel or gestodene. The shift to third generation pills in the early 1990s was largely based on claims of superior cardiovascular safety. We now have evidence on which to assess these claims A lower risk of myocardial infarction in users of third compared with users of second generation pills was found in the Transnational study, although not in the British subgroup or in women aged under 35.2 However, the results did not take account of product specific differences in screening for hypertension before women started using the pill, which had a large effect in users of second generation pills (MA Lewis, personal communication). A similar influence had previously been found in the World Health Organisation study: in women whose blood pressure had been checked, the difference between the pill generations disappeared.3 It seems that undiagnosed hypertension was more common in second generation users …Keywords
This publication has 11 references indexed in Scilit:
- Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95BMJ, 1999
- Venous thromboembolism amng new users of different oral contraceptives.The Lancet, 1999
- Oral contraceptives and venous thromboembolismContraception, 1998
- Newer Oral Contraceptives and the Risk of Venous ThromboembolismContraception, 1998
- The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young womenContraception, 1997
- Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.1997
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.1995
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995